The Shotlee Journal
Browse Shotlee articles about Weight Management.
Showing 9 / 872 Weight Management articles
A 30-year-old woman from East Anglia discovered her rare gigantomastia condition—causing her breasts to weigh 39 lbs.—while losing weight on Mounjaro. Despite rapid breast growth amid overall weight loss, she faces numb arms, scarring, and breathing issues. Her story highlights the unexpected challenges of GLP-1 medications like tirzepatide.
A Liverpool mum shed 7st on Mounjaro in under a year, transforming her life—but a freezing side effect dubbed 'MJ Freeze' has spiked her energy bills by £70 a month. Emilly Murray now layers up at home with heated blankets and gloves just to stay warm. Despite the chill, she says it's worth every penny for silencing food noise and boosting her health.
Hims & Hers Health's bold launch of a $49-per-month copycat GLP-1 pill to rival Wegovy's $149 price tag backfired spectacularly. FDA Commissioner Marty Makary vowed 'swift action' against such unapproved drugs, sending HIMS shares down 7.5% in premarket trading. This regulatory showdown highlights growing tensions in the GLP-1 market dominated by Novo Nordisk and Eli Lilly.
Renowned Slovak singer Brigita Szelidová revealed that Ozempic, prescribed for her diabetes, led to a dramatic loss of her vocal range, making even simple songs challenging. With over 30 years in the industry, her story highlights emerging concerns about GLP-1 drugs like Ozempic and Wegovy affecting performers' voices. As off-label weight loss use surges, professionals in music and opera weigh the benefits against unforeseen vocal risks.
Eli Lilly posted blockbuster Q4 2025 results with $19.29B revenue, yet shares near $1,020 face selling pressure from compounded semaglutide competition and government pricing initiatives. Hims & Hers' $49 pill undercuts Zepbound's $299 intro dose, signaling shifts in the GLP-1 market. Investors eye Orforglipron's FDA decision amid pipeline cuts.
Hims & Hers launched a $49-a-month compounded version of Novo Nordisk's Wegovy, promising affordable GLP-1 weight-loss treatment amid shortages. Yet, despite an initial 14% stock surge, shares closed down 4% as FDA scrutiny loomed. This move highlights tensions in the booming obesity drug market and accessibility challenges for patients.
Novo Nordisk's shares rebounded 4.7% in early trading on Friday after the FDA vowed to crack down on companies mass-marketing illegal copies of Wegovy. This followed a sharp sell-off triggered by Hims & Hers' launch of a cheap $49 compounded version. Understand the safety risks and what this means for GLP-1 patients seeking approved weight-loss treatments.
As millions use GLP-1 medications like Ozempic for weight loss, clinicians are seeing a rise in new eating disorders dubbed 'agonorexia.' These drugs' powerful appetite suppression may drive dangerous food and body image obsessions, even in those without prior history. Experts warn current screening may miss at-risk patients.
Shares in Novo Nordisk, maker of Ozempic and Wegovy, plunged 18% after a sales warning flagged up to 13% decline in the US market due to falling GLP-1 drug prices. Despite 2025 sales growth of 6% to 309 billion kronor, the stock wipeout erased $32 billion in value. CEO Mike Doustdar highlights the upcoming Wegovy pill as a key future driver.
